BioWorld MedTech

Feb. 11, 2015

Agendia receives new FDA clearance for MammaPrint

Molecular diagnostics company Agendia (Irvine, California) reported that it has received FDA 510(k) clearance for its MammaPrint breast cancer recurrence test in FFPE (formalin-fixed paraffin embedded) tissue. Read More

Latin America: Venezuela turns to China to alleviate medical device shortage

MDD Interview: French crowds say 'oui' to funding as EyeBrain raises $1.5 million

Inside the Beltway: AdvaMed highlights coverage of FDA-approved medical device trials

World in Review: Data from British Journal of Surgery supports Medtronic's ClosureFast

Seeking tax reform, U.S. Senate committee examines 1986 overhaul

Agreements/contracts: CWRU, Cleveland Clinic win DoD bid for prosthetic limb research

Financings: AxoGen closes public offering of stock for around $13 million

People in Places

Patent Watch: HCi Viocare files application for wearable devices, motion capture

Product Briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

Genescience presents STAT6 degrader for atopic dermatitis

BioWorld Science

Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....

Roche reports new TREM2 agonists

BioWorld Science

F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...